111 Capital Invests $1.15 Million in Medtronic PLC $MDT

111 Capital acquired a new stake in Medtronic PLC (NYSE:MDT) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 12,036 shares of the medical technology company’s stock, valued at approximately $1,146,000.

Several other hedge funds also recently bought and sold shares of MDT. Norges Bank purchased a new position in shares of Medtronic during the 2nd quarter valued at $1,432,698,000. Guinness Asset Management LTD bought a new stake in Medtronic during the third quarter valued at $275,556,000. Vanguard Group Inc. grew its position in Medtronic by 1.5% during the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after buying an additional 1,895,165 shares in the last quarter. Magellan Asset Management Ltd purchased a new position in Medtronic during the third quarter worth about $126,347,000. Finally, Bessemer Group Inc. increased its stake in Medtronic by 86.2% in the 3rd quarter. Bessemer Group Inc. now owns 2,538,029 shares of the medical technology company’s stock worth $241,723,000 after acquiring an additional 1,174,765 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

MDT has been the subject of several recent analyst reports. Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a report on Sunday. Sanford C. Bernstein lifted their target price on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Daiwa Securities Group decreased their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday. Leerink Partners lowered their price objective on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 18th. Finally, UBS Group reaffirmed a “neutral” rating and set a $104.00 price objective on shares of Medtronic in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

Medtronic Price Performance

Shares of Medtronic stock opened at $97.60 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a fifty day moving average of $98.93 and a 200-day moving average of $96.92. The stock has a market capitalization of $125.31 billion, a price-to-earnings ratio of 27.19, a price-to-earnings-growth ratio of 2.45 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the previous year, the firm posted $1.38 earnings per share. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s payout ratio is presently 79.11%.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).